CRISPR Therapeutics ($CRSP) Stock Hub: CASGEVY, CTX310 and the 2026 In Vivo Pipeline

01 Latest verified update — September 6, 2026: a year of CTX310 durability, silence on EDGAR and the stock below $56

What came out after August 28, 2026. Nothing. The company’s release feed stops at the ESC presentation of August 28 and the latest EDGAR filing is the Orbis and Allan Gray Schedule 13G/A of August 14, 2026 (5.6%). No Form 8-K, no offering, no new date. Guidance is unchanged from the release: a CTX310 Phase 1b update in the second half of 2026 in patients with severe hypertriglyceridemia.

The market at September 4, 2026. Nasdaq close of $55.79, down 3.3% from the $57.72 of August 28, the day of the data; market capitalisation of about $5.39 billion on the 96,692,653 shares of the 10-Q cover (Merlintrader calculation). Adding the $586 million carrying value of the converts and subtracting the $2,364 million of liquidity at June 30 gives an enterprise-value proxy of roughly $3.62 billion. Short interest 20.88% of the float (18.74 million shares, 11.51 days to cover), institutional 73.22%, insiders 7.16%, Finviz aggregate analyst target $84.72. On Stocktwits at September 6, 2026 the normalised score was 36 out of 100 (bearish label) while 92.9% of tagged messages were bullish: the two indicators diverge and both are opinions of non-professional traders.

Why the count matters. The cover says 96.69 million shares, but the 10-Q lists 16.767 million equivalents excluded from diluted EPS (converts at the initial conversion rate, options, RSUs, ESPP) and $557.2 million of gross ATM capacity unused in the first half of 2026, on top of the Swiss capital band of up to 18.795 million shares valid until June 8, 2028. None of these is dilution in progress; all of them are dilution that can happen.

What did not change. CASGEVY remains a Vertex product in the accounts, with CRSP entitled to 40% of the program’s net profit and, until the program is profitable, booking a net collaboration expense. CTX310 answered the one-year durability question in 15 participants; it did not, and could not, answer the questions about cardiovascular events and long-term safety at larger numbers. The runway of at least 24 months is company guidance and excludes new collaboration or financing proceeds.

02 Executive summary and investor readout

CRISPR Therapeutics is different from most public gene-editing companies because its founding technology has already produced an approved medicine. CASGEVY validates that ex vivo CRISPR/Cas9 editing can reach regulators, manufacturing networks and patients. That achievement is scientifically important, but it does not settle the stock debate. The commercial product is partnered, logistically demanding and still loss-making for CRSP on the collaboration line. Meanwhile, most of the valuation upside investors discuss now depends on programs that are earlier, broader and technically different from CASGEVY.

The central question is therefore simple to state and difficult to answer: can CRSP scale beyond one partnered ex vivo therapy into a repeatable in vivo and allogeneic-cell platform? CTX310 is the most immediate test. Zugo-cel is the most advanced second-franchise opportunity. CTX340, CTX460, CTX321, CTX611 and CTX213 add optionality, but also create execution load and future spending.

What changed since the previous CRSP report

The current company is not the one captured by the older Merlintrader coverage. CASGEVY has moved from approval into measurable launch acceleration; the U.S. label has expanded to children aged two and older; CTX310 has produced initial human lipid data and entered Phase 1b; CTX340 and CTX460 have moved into company-reported Phase 1 activity; CTX611 is in a 450-participant Phase 2 study; and zugo-cel has expanded across oncology and autoimmune disease. At the same time, CRSP issued $600 million of 2031 convertible notes, which strengthened liquidity but changed the capital structure.

Read the archived CRSP report for historical context. This Stock Hub is the current, living reference and should control when facts conflict.

03 Company, platform and the real valuation problem

CRISPR Therapeutics was built around CRISPR/Cas9, a system that uses a guide RNA to direct a nuclease to a selected DNA sequence. The attraction is precision and durability: a single intervention may create a permanent change. The same permanence raises the cost of error. An off-target edit, an unintended on-target consequence or a delivery problem cannot be treated like the temporary exposure from a conventional small molecule.

The portfolio now spans several modalities. CASGEVY edits a patient’s own blood stem cells outside the body. CTX310, CTX340, CTX321 and CTX460 seek to edit liver cells in vivo through lipid-nanoparticle delivery. Zugo-cel is an off-the-shelf allogeneic CAR-T product. CTX611 is an siRNA program obtained through the Sirius collaboration. CTX213 is a next-generation cell-replacement concept for type 1 diabetes. These are not interchangeable assets: they share corporate infrastructure and some scientific capabilities, but each has a different delivery, manufacturing, safety and regulatory risk.

The valuation problem is not “does CRISPR work?” CASGEVY answers part of that question. The harder issue is how much probability and commercial value to assign to a set of programs that remain early. At the September 4, 2026 close, market capitalization was about $5.39 billion and a simple enterprise-value proxy was about $3.62 billion after subtracting cash and adding convertible debt. That means the market was already assigning billions to CASGEVY economics, the pipeline and the platform. Cash is a cushion, not the whole thesis.

04 CASGEVY: validation, adoption and the accounting investors must understand

CASGEVY, or exagamglogene autotemcel, is an autologous edited hematopoietic stem-cell therapy for sickle-cell disease and transfusion-dependent beta thalassemia. Patient cells are collected, edited outside the body to increase fetal hemoglobin, and reinfused after myeloablative conditioning. The therapy can be transformative, but the process requires specialized centers, manufacturing coordination, conditioning, inpatient support and long follow-up. Commercial adoption therefore cannot be modeled like a prescription medicine that moves directly from diagnosis to pharmacy.

Launch trajectory

Vertex reported $116 million of CASGEVY product revenue for full-year 2025, approximately $42.9 million in Q1 2026 and $76 million in Q2 2026. First-half 2026 sales of roughly $118.9 million already exceeded full-year 2025. CRSP reported approval in 39 countries, and German reimbursement for eligible patients aged 12 and older was obtained in May 2026. These are meaningful signs that the launch is moving beyond a symbolic first year.

The July 1, 2026 FDA label expansion to patients aged two and older in both indications is strategically important. The companies estimated that roughly 5,500 additional U.S. patients became eligible. In the pediatric evidence cited by FDA, all eight efficacy-evaluable sickle-cell patients achieved at least 12 consecutive months without severe vaso-occlusive crises, while eight of nine efficacy-evaluable TDT patients achieved at least 12 months of transfusion independence. The numbers are small, and efficacy in the youngest patients was partly extrapolated. Conditioning, engraftment, hypersensitivity and off-target risks remain material.

The European authorization remained conditional and restricted to patients aged 12 and older at the research cut-off. Investors should not assume that the U.S. pediatric label automatically applies elsewhere.

The 40% economics are not a 40% royalty

The agreement allocates program profit and loss 60% to Vertex and 40% to CRSP. CRSP does not book 40% of gross sales as its own revenue. Manufacturing, commercialization and continuing development expenses are accounted for before distributable profit emerges. That makes a conventional price-to-sales multiple misleading and prevents an outside investor from estimating break-even without product-level costs, patient flow and cash-settlement detail that the companies do not disclose.

There is another layer. CRSP deferred $221.8 million of CASGEVY costs incurred in 2022–2024. Those amounts may be recovered by Vertex through offsets against future CRSP profit allocations, subject to an annual cap. No contingent liability was accrued at June 30, 2026 because recovery was not yet considered probable and estimable. The deferral protected earlier cash, but it may delay some future cash profit even after the program turns economically positive.

What to monitor each quarter

• Sequential CASGEVY product revenue at Vertex, with explicit separation from CRSP-reported revenue.
• Whether CRSP’s collaboration expense, net, shrinks toward zero and eventually turns into income.
• Patient starts, collections, infusions and treatment-center activation if the companies disclose them.
• Reimbursement additions and the conversion of pediatric eligibility into real treatment volumes.
• Manufacturing capacity, vein-to-vein timing and any safety or long-term follow-up disclosures.
• Recognition or use of the rare-pediatric-disease priority-review voucher economics.

05 Pipeline map: current status and evidence quality

Programs absent from current company materials require careful language. CTX320 produced earlier Lp(a) data, but the company now highlights CTX321, which uses a new guide RNA reported to be about twice as potent preclinically. No formal discontinuation announcement for CTX320 was identified. Likewise, CTX131 trials are listed as completed and the asset is absent from current updates, supporting “apparently deprioritized” but not a definitive claim that development was terminated.

06 CTX310: the most important test of the in vivo platform

CTX310 is designed to make a permanent edit to ANGPTL3 in liver cells after a single lipid-nanoparticle infusion. ANGPTL3 is an established lipid target, and genetic evidence supports the idea that lower activity can reduce triglycerides and LDL. The commercial ambition is potentially much larger than a rare-disease product, but the proof standard is also higher because cardiovascular medicine already has effective chronic therapies with long safety histories.

What the one-year follow-up showed, on August 28, 2026

CRSP presented the durability data in a late-breaking session at the European Society of Cardiology Congress 2026 and published them the same day in the New England Journal of Medicine under the title “Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310”. The measurement point is one year after a single intravenous infusion, and every one of the 15 participants had reached at least twelve months of follow-up at the data cut-off.

Reductions in circulating ANGPTL3 were dose dependent and were sustained through the year; among participants treated at 0.8 mg/kg the company reported reductions of up to 89%, with a mean of 79% at twelve months. These figures are not a revision of the numbers below: they are a different time point. The November 2025 release measured the initial treatment period, this one measures where those curves sit a year later, which is why the triglyceride and LDL means move in opposite directions from each other between the two readouts.

Safety at extended follow-up

No new treatment-related safety events were observed during the extended follow-up. There were no dose-limiting toxicities and no treatment-related serious adverse events, and adverse events were described as generally mild to moderate. The events already on the record stay on the record and were reported in Laffin et al. in the New England Journal of Medicine in 2025: one allergic reaction that resolved the following day with supportive care, and three Grade 2 infusion-related reactions, two at 0.6 mg/kg and one at 0.8 mg/kg, all of which resolved with the infusions completed. Beyond the transient aminotransferase elevation previously reported in one participant shortly after treatment, the company reported no liver function test elevations through the remainder of the trial, and no Grade 3 or worse changes in liver transaminases.

The trial that produced these numbers

The Phase 1a portion was an open-label dose-escalation study of single-course intravenous CTX310 at 0.1 to 0.8 mg/kg of lean body weight, across cohorts labelled DL1 (0.1), DL2 (0.3), DL3 (0.6), DL3.5 (0.7) and DL4 (0.8). It enrolled four patient groups: homozygous familial hypercholesterolemia, severe hypertriglyceridemia, heterozygous familial hypercholesterolemia, and mixed dyslipidemias with both elevated triglycerides and LDL. Eligible participants had uncontrolled triglycerides above 150 mg/dL and/or LDL cholesterol above 100 mg/dL, or above 70 mg/dL for those with established atherosclerotic cardiovascular disease, despite background standard of care. Most were on statins or ezetimibe and 40% were taking PCSK9 inhibitors, which matters: the reductions were measured on top of therapy, not instead of it. Safety and tolerability were the primary endpoints; change in circulating ANGPTL3, triglycerides and LDL were secondary.

What the November 2025 dataset had shown

In the November 2025 Phase 1 update, CRSP reported no dose-limiting toxicity or treatment-related serious adverse event. At the highest dose, mean reductions were 73% for ANGPTL3, 55% for triglycerides and 49% for LDL, with maximum reductions of 89%, 84% and 87%, respectively. Among participants with elevated baseline triglycerides, the company reported a 60% mean triglyceride reduction at therapeutic doses.

Safety disclosures included a resolved allergic reaction, three Grade 2 infusion-related reactions and a Grade 2 transaminase increase in a participant whose liver enzymes were already elevated at baseline; it resolved by Day 14. A later presentation also identified serious events judged unrelated, including one unrelated death at the lowest dose 179 days after treatment. These details do not negate target engagement, but they are essential context for a permanent therapy.

What the ESC update answered, and what it did not

Two limits survive the readout, and they are the reason a durable biomarker effect is not the same thing as a proven medicine. The first is arithmetic: fifteen participants in an open-label, single-arm dose-escalation study cannot characterise the frequency of rare events, and the safety of an edit that cannot be reversed is a long-horizon question that one year of follow-up begins rather than settles. The second is the endpoint: ANGPTL3, triglycerides and LDL are surrogates that regulators and payers accept in some contexts and not in others, and a lipid-lowering agent competing against statins, ezetimibe and PCSK9 inhibitors is eventually judged on cardiovascular events, which no CTX310 study has measured.

The registered open-label, single-arm study is recruiting and lists an estimated 90 participants, with estimated primary completion in June 2027. That registry date is an operating estimate—not a company-promised topline catalyst.

07 Zugo-cel: a possible second franchise with small-n evidence

Zugo-cel, formerly CTX112 and most recently described as zugocabtagene geleucel, is an allogeneic anti-CD19 CAR-T. The off-the-shelf model aims to provide a manufactured donor-derived product without the individualized production required for autologous CAR-T. CRSP is evaluating the asset across B-cell malignancies and several autoimmune settings, including rheumatologic disease, ITP/warm autoimmune hemolytic anemia and neurologic autoimmune disease.

Oncology signal

At the 600-million-cell dose in the December 2025 update, CRSP reported a 90% overall response rate, or 9 of 10 patients, and a 70% complete-response rate, or 7 of 10. Among only three patients with one-year follow-up, two remained in complete response. In 12 large-B-cell lymphoma patients treated at the recommended Phase 2 dose, Grade 3 cytokine-release syndrome and Grade 3 ICANS were each reported in 17%, and serious infections in 8%.

The FDA has granted RMAT designation in relapsed or refractory follicular lymphoma and marginal-zone lymphoma. That designation can increase regulatory interaction; it does not establish efficacy or guarantee approval. A pirtobrutinib combination with Lilly has been initiated according to CRSP, although a separately identifiable public registry arm was not available at the cut-off.

Autoimmune opportunity

The initial autoimmune release covered four patients at a lower dose. All showed clinical improvement by Day 28, and the first systemic-lupus patient achieved drug-free DORIS remission through month six. A later company presentation said more than 14 autoimmune patients had been dosed and that the first two SLE patients remained in DORIS remission at months 12 and six. Those observations are promising but preliminary, non-randomized and distributed across distinct diseases.

The key value proposition is not merely a high early response rate. Zugo-cel must show that an allogeneic product can expand and persist enough to create deep, durable B-cell depletion while keeping CRS, neurotoxicity and infection competitive. In autoimmune disease, durable drug-free remission and immune reset matter more than a short-lived laboratory response.

08 The rest of the pipeline: CTX340, CTX460, CTX321, CTX611 and CTX213

CTX340: AGT editing for refractory hypertension

CTX340 is designed to reduce angiotensinogen through a permanent liver edit. The FDA cleared the IND and the Phase 1/2 study is listed as recruiting with an estimated 69 participants. Hypertension is a vast market, but the initial addressable group is appropriately narrower: patients who remain uncontrolled despite existing therapies. A one-time treatment must demonstrate a dependable dose-response, durable blood-pressure reduction and an especially reassuring safety profile.

CTX460: SyNTase-based SERPINA1 correction in alpha-1 antitrypsin deficiency

CTX460 is intended to correct the disease-causing SERPINA1 sequence rather than simply knock down a protein. CRSP calls it the first SyNTase program and reported that Phase 1 had been initiated. The published evidence remains preclinical: the company reported more than 90% mRNA correction, a fivefold increase in total AAT and a greater-than-99% M-AAT to Z-AAT serum ratio in models. These are company-reported model results, not human efficacy. No public NCT was identified at the cut-off, so the Hub does not claim that a first patient has been dosed.

CTX321: iteration after CTX320

The Lp(a) program is now represented by CTX321, a next-generation candidate with a new guide RNA that CRSP says is roughly twice as potent preclinically using the same LNP system. It should not be described as a simple rename of CTX320. The transition illustrates one advantage of a platform—rapid iteration—but also shows that early candidates can be superseded before the market receives a clean development conclusion.

CTX611: a Phase 2 siRNA asset

CTX611, formerly SRSD107, targets Factor XI through siRNA rather than gene editing. The Phase 2 total-knee-arthroplasty study compares the asset with enoxaparin and plans about 450 participants. CRSP and Sirius share costs and profits equally; CRSP is expected to lead a global Phase 3 outside Greater China and U.S. commercialization, while Sirius leads Greater China. A second-half 2026 update could determine whether this non-core modality becomes a credible late-stage asset.

CTX213: deviceless beta-cell replacement

CTX213 is a next-generation, preclinical iPSC-derived beta-cell replacement concept for type 1 diabetes. It follows learning from CTX211, where early patients showed detectable C-peptide but the device experienced fibrosis limitations. Removing the device may solve one problem while increasing the need for reliable immune evasion, engraftment, control and long-term tumor surveillance. It remains optionality, not a clinical valuation anchor.

09 Financial position: unusually strong liquidity, still meaningful burn

At June 30, 2026, CRSP held $291.3 million of cash and equivalents and $2.073 billion of marketable securities, for total liquidity of $2.364 billion. It reported $586.2 million as the carrying value of long-term convertible debt, $904.2 million of total liabilities and $1.747 billion of shareholders’ equity. Net cash after the note carrying value was approximately $1.778 billion.

Management’s stated runway is the correct public anchor: existing cash, equivalents and securities should fund operating expenses and capital expenditure for at least the next 24 months, excluding additional financing or partnership proceeds. A mechanical division of gross liquidity by the derived Q2 cash use produces about 7.1 years, but that is not guidance and is too optimistic as a planning assumption. It freezes spending even as several programs enter more expensive clinical stages and ignores business development, manufacturing and commercial obligations.

Derived valuation snapshot

At the $55.79 close of September 4, 2026, market capitalization was approximately $5.394 billion on the July 31 share count. Adding $586 million of debt and subtracting $2.364 billion of liquidity gives a simple enterprise-value proxy of roughly $3.617 billion. Cash and securities were about $24.45 per July 31 share; net cash after convertible debt was about $18.39 per share. These are Merlintrader calculations, not company guidance, and they exclude lease and other valuation nuances.

10 Capital structure and dilution map

Convertible notes due 2031

CRSP issued $600 million principal of convertible senior notes in March 2026 and received about $585.4 million net. The notes mature March 1, 2031. Their gross contractual coupon is 1.7308%, structured to deliver an intended 1.125% effective coupon to holders after anticipated Swiss withholding. The initial conversion price is approximately $76.56 per share.

Initial conversion would represent about 7.837 million shares; the maximum under specified adjustments is about 11.364 million. At the September 4, 2026 close of $55.79, the stock traded well below the initial conversion price of about $76.56. These shares are potential, not current, dilution. Nevertheless, base conversion would equal roughly 8.1% of the July 31 share count, while the contractual maximum would equal about 11.8%.

ATM and other authorization

The separately identified 2025 at-the-market program had $557.2 million of gross capacity remaining at June 30, after prior issuance of about 0.7 million shares at an average $60.81. No ATM shares were sold in the first half of 2026. At the $55.79 close of September 4, 2026, using the entire remaining capacity would require roughly 10.0 million shares, about 10.3% of the current count. This is a price-dependent illustration, not a forecast.

The Swiss capital band authorized up to 18.795 million shares at quarter-end through no later than June 8, 2028 unless changed or exhausted. Authorization does not mean management plans to issue all of those shares. It does show that strong gross cash does not eliminate corporate flexibility to raise equity.

Options, unvested restricted shares, ESPP awards and assumed note conversion totaled 16.767 million potential common equivalents excluded from diluted EPS because the company reported a loss. Historical dilution is also relevant: shares outstanding increased about 11.8% during 2025, driven in part by sizeable ATM issuance and Sirius consideration. Per-share analysis must therefore use the current and fully diluted architecture, not only market capitalization.

11 Ownership, management, short positioning and governance

CRSP is led by chief executive and board chair Samarth Kulkarni, who has served as CEO since December 2017 and became chair in 2023. Combining both roles can support strategic continuity, but it concentrates leadership authority and makes independent board oversight a governance item worth monitoring. This is a structural observation, not an allegation about conduct.

Dated beneficial-ownership filings are more reliable than generic aggregator percentages. ARK reported 11.313 million shares, or 11.79%, as of March 31, 2026. BlackRock reported 7.987 million shares, or 8.3%, as of June 30. Orbis/Allan Gray reported a combined 5.449 million shares, or 5.6%, and Capital World Investors reported 4.929 million, or 5.1%, on its March 31 event date. These positions can change after the filing date and should not be read as endorsements of the current price.

Finviz Elite reported short interest at 20.88% of the float (18.74 million shares) with a short ratio of 11.51 days on September 4, 2026. The earlier market-data estimate for the July 31 settlement showed about 19 million shares short, roughly 19.1% of shares outstanding and 11.5 days to cover; the two are measured against different bases, float in one case and shares outstanding in the other, which is part of why they differ. Because a directly retrieved security-level exchange file was not available for either, neither is treated as primary evidence. The practical message is positioning: a large short base can amplify both downside after disappointing data and upside during a squeeze. It does not prove either fundamental case.

The Finviz aggregate of sell-side price targets stood at $84.72 on September 4, 2026, against the $55.79 close of the same day. It is an aggregation of third-party views, not a Merlintrader estimate, and free data sources still conflict on analyst count and target methodology, which is why no single consensus number is treated here as authoritative. Omitting a weak number is more informative than creating false precision.

12 Competition: compare programs, not gene-editing slogans

CRSP competes at several levels. In sickle-cell disease and beta thalassemia, CASGEVY competes for treatment-center capacity, eligible patients and payer support with Bluebird Bio’s lovo-cel/Zynteglo franchise, conventional transplantation and rapidly improving supportive care. The differentiation is not only efficacy; conditioning burden, manufacturing reliability, time to treatment, safety follow-up and reimbursement shape adoption.

In liver editing, Intellia Therapeutics provides the clearest public-company in vivo editing comparison, while Beam Therapeutics offers a base-editing alternative in selected liver diseases. Prime Medicine is earlier and uses prime editing. Modality labels are not outcomes: delivery, dose, edit precision, durability and development path matter more than whether the corporate presentation says CRISPR, base editing or prime editing.

CTX310 enters lipid medicine where monoclonal antibodies, siRNA, antisense and oral drugs already set strong safety and efficacy benchmarks. A permanent one-time treatment may improve adherence, but it must justify irreversible exposure and potentially long follow-up. CTX321 faces an increasingly crowded Lp(a) field with several advanced non-editing programs. Zugo-cel competes with approved autologous CAR-T, other allogeneic platforms and emerging bispecific antibodies; in autoimmune disease it must ultimately compare with conventional immunosuppression and other CD19-directed cell therapies.

CASGEVY is partnered with Vertex Pharmaceuticals, which is both a strategic strength and an economic limitation. Vertex contributes global commercial and manufacturing capability; CRSP accepts minority economics and reduced control. Investors should evaluate the partnership as an operating architecture, not simply as validation by a larger company.

13 Catalyst calendar and evidence hierarchy

No issuer-guided 2027 milestone was identified at the cut-off. ClinicalTrials.gov lists estimated primary-completion dates, including June 2027 for CTX310, but registry estimates are not promised data-readout dates and can change.

Evidence hierarchy used by this Hub

1. Regulatory actions and filed financial statements: highest confidence for approvals, obligations, cash, debt and reported expenses.
2. Registered trial status: confirms protocol and recruitment information, but registry dates remain estimates.
3. Patient-level clinical data: most decision-useful when cohort size, follow-up, endpoints and safety are clear.
4. Company presentations and releases: useful primary sources, but forward-looking and often selective.
5. Preclinical evidence: supports mechanism and candidate selection; it cannot establish human benefit.
6. Third-party market data: appropriate for price and positioning snapshots only when timestamped and clearly labeled.

14 Bull, base and bear scenarios

Thesis breakers and disconfirming evidence

• CASGEVY sequential sales momentum stalls after the pediatric label expansion, or net collaboration expense does not improve as revenue scales.
• CTX310 biomarkers rebound materially, responses vary widely at the selected dose, or liver, immune, off-target or other safety findings worsen with follow-up.
• The regulatory route for CTX310 requires lengthy outcome trials without a viable commercial or partnership plan.
• Zugo-cel response rates, complete responses or drug-free autoimmune remissions deteriorate in larger cohorts.
• CRS, ICANS, infection, persistence or manufacturing results make zugo-cel uncompetitive with autologous or other allogeneic approaches.
• CTX321 does not enter the clinic or fails to show a practical advantage over CTX320 and non-editing Lp(a) competitors.
• CTX340 and CTX460 remain described as initiated without visible patient dosing or development progress.
• Operating cash use accelerates as the company expands the portfolio without prioritizing the programs that can create decisive evidence.
• ATM issuance, stock compensation or note conversion grows the share count materially before value-inflecting data.

15 Monitoring checklist for every CRSP update

Retail sentiment can help explain volatility, but it is not included as a factual thesis input unless sourced to a dated, reproducible sample. CRSP’s elevated short positioning and event calendar make social narratives especially unstable around data releases. Clinical protocol, filed economics and patient-level evidence take priority.

16 CRSP Stock Hub FAQ

Does CRISPR Therapeutics receive 40% of CASGEVY sales?

No. Vertex records sales. Vertex and CRSP share the program’s net profits and losses 60/40 after relevant costs. CRSP can therefore report a net collaboration expense even while CASGEVY revenue grows.

What is the next CRSP catalyst?

The CTX310 Phase 1a durability presentation at ESC Congress 2026 took place on August 28, 2026, with simultaneous publication in the New England Journal of Medicine. The nearest guided item is now the CTX310 Phase 1b update on the severe hypertriglyceridemia cohort, expected in the second half of 2026. Zugo-cel and CTX611 updates are guided for the same window. None of them carries a fixed date.

Is CTX310 already proven to reduce cardiovascular events?

No. The first 15-patient dataset showed substantial changes in ANGPTL3, triglycerides and LDL. Those are biomarkers. The program has not demonstrated a reduction in heart attacks, strokes or mortality.

Is zugo-cel the same product as CTX112?

Yes. Zugo-cel is the current name for the allogeneic anti-CD19 CAR-T previously called CTX112. The latest company materials use the generic spelling zugocabtagene geleucel.

Was CTX320 renamed CTX321?

No. CRSP describes CTX321 as a next-generation Lp(a) candidate with a new guide RNA. CTX320 is absent from current updates, but no formal discontinuation announcement was identified at the cut-off.

How much cash does CRSP have?

At June 30, 2026, cash, equivalents and marketable securities totaled $2.364 billion. The company also carried $586.2 million of convertible debt. Management said liquidity should cover at least the next 24 months; longer mechanical estimates are not guidance.

Can the 2031 convertible notes dilute shareholders?

Potentially. Initial conversion represents about 7.837 million shares at an initial conversion price near $76.56, with a higher contractual maximum under specified adjustments. Conversion shares were not included in diluted EPS because the company reported a loss.

Why is CRSP compared with BEAM, NTLA and PRME?

All four provide public-market exposure to differentiated gene-editing platforms. CRSP has approved-product validation; NTLA has prominent in vivo clinical experience; BEAM uses base editing; and PRME uses prime editing. The relevant comparison is human evidence, delivery, safety, financing and development path—not the platform slogan.

Is this Hub a recommendation to buy or sell CRSP?

No. It is an educational research framework. CRSP is a volatile biotechnology equity exposed to clinical, regulatory, commercial, financing and market risk. Any investment decision requires independent due diligence and consideration of individual circumstances.